Real World Evidence in Life Sciences: What Happens After Clinical Trials?

Whitepaper | SAS

Real World Evidence in Life Sciences: What Happens After Clinical Trials?

Life sciences companies are being asked by regulators, payers, providers and patients to prove therapies measure up to their promise in the real world. That desire actually creates an incredible opportunity to gain insights from tens of thousands of patients versus the limited population of a clinical trial because transforming HEOR data into real-world evidence gives a clearer picture of product safety and effectiveness, economics and value in actual use. This paper discusses: how using advanced analytics helps bridge the data-to-evidence gap, allowing integration and management of diverse data sources; fit-for-purpose analytical applications; scalable, high-performance computing power; and the option to move to the cloud.